The Latest
-
Q&A
Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”
-
Who’s getting left behind in the weight loss bonanza?
As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.
-
Q&A
An ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
-
Profile
The pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle
After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.
-
Orchard sets out to sell world’s priciest gene therapy
Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.
-
With historic MASH approval, Madrigal preps for launch and a public offering
After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.
-
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.
-
Q&A // Biotech Spotlight
GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
-
5 Big Pharma CEOs who saw major pay bumps in 2023
Pharma’s recent wins have led to pay windfalls for several company leaders.
-
Ex-Novartis exec sets out to create ‘Apple of AI’
Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.
-
After Amylyx drug failure, what’s next for ALS?
The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.
-
Q&A
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
-
These biotech hotspots are ripe for IPOs
Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.
-
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
-
As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
-
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.
-
Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D
The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.
-
Q&A
Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
-
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
Updated March 8, 2024 -
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.
-
Could pharma’s legal attack on the IRA succeed in killing price negotiations?
An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.
-
Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches
Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.
-
Profile
HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
-
Biotech IPOs heated up to start 2024. Will the surge last?
Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead.
-
Biotech Spotlight
Black Diamond looks to outwit cancer mutations
Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.